They wait for a quarterly conference and then stuff negative developments way down inside a document so hopefully no one will see it? I refer you to page 19. Its states..."Our collaborative research and development agreements may be terminated or allowed to expire. In April 2014, we received a notice from GlaxoSmithKline of its intent to terminate the development of foretinib and return the compound to us pursuant to the terms and conditions of the product development and commercialization agreement between the parties. Once foretinib is returned to us, we will no longer be eligible to receive milestones or royalties from our collaborative arrangement with GlaxoSmithKline." Sounds like a significant piece of news to me. Are they in the habit of not releasing significant details as they occur and then hiding them in the 10Q? Pretty slimy tactic if you ask me. Especially since they have not updated the website and it still shows this as ongoing program at the top of the Partnered Compounds list.